{
    "ticker": "CLSD",
    "name": "Clearside Biomedical, Inc.",
    "description": "Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing innovative therapies to treat serious eye diseases. Founded in 2011 and based in Alpharetta, Georgia, Clearside is at the forefront of ocular drug delivery technology. The company aims to revolutionize the treatment of retinal diseases by utilizing its proprietary suprachoroidal injection platform, which allows for targeted delivery of therapeutic agents to the back of the eye. This approach minimizes systemic exposure and enhances the efficacy of treatments for conditions such as uveitis, macular edema, and other retinal disorders. The company's lead product candidate, XIPERE\u2122 (triamcinolone acetonide), has received FDA approval for the treatment of macular edema associated with uveitis. Clearside is committed to advancing its pipeline of product candidates and exploring collaborations to expand its impact on the field of ophthalmology. With a dedicated team of scientists and industry professionals, Clearside strives to improve patient outcomes and address unmet medical needs in the rapidly evolving field of eye care.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Alpharetta, Georgia, USA",
    "founded": "2011",
    "website": "https://www.clearsidebio.com",
    "ceo": "George Lasezkay",
    "social_media": {
        "twitter": "https://twitter.com/ClearsideBio",
        "linkedin": "https://www.linkedin.com/company/clearside-biomedical/"
    },
    "investor_relations": "https://ir.clearsidebio.com",
    "key_executives": [
        {
            "name": "George Lasezkay",
            "position": "CEO"
        },
        {
            "name": "John D. G. H. D. Shuman",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "XIPERE\u2122"
            ]
        }
    ],
    "seo": {
        "meta_title": "Clearside Biomedical, Inc. | Innovative Ocular Therapies",
        "meta_description": "Clearside Biomedical is a biopharmaceutical company developing innovative therapies for serious eye diseases. Learn more about their pioneering work in ocular drug delivery.",
        "keywords": [
            "Clearside Biomedical",
            "Ocular Therapies",
            "Retinal Diseases",
            "Biopharmaceuticals",
            "Eye Care",
            "XIPERE"
        ]
    },
    "faq": [
        {
            "question": "What is Clearside Biomedical known for?",
            "answer": "Clearside Biomedical is known for developing innovative therapies for serious eye diseases, particularly using its suprachoroidal injection platform."
        },
        {
            "question": "Who is the CEO of Clearside Biomedical?",
            "answer": "George Lasezkay is the CEO of Clearside Biomedical, Inc."
        },
        {
            "question": "Where is Clearside Biomedical headquartered?",
            "answer": "Clearside Biomedical is headquartered in Alpharetta, Georgia, USA."
        },
        {
            "question": "What is Clearside's lead product candidate?",
            "answer": "Clearside's lead product candidate is XIPERE\u2122, approved for the treatment of macular edema associated with uveitis."
        },
        {
            "question": "When was Clearside Biomedical founded?",
            "answer": "Clearside Biomedical was founded in 2011."
        }
    ],
    "competitors": [
        "REGN",
        "BMY",
        "AMGN"
    ],
    "related_stocks": [
        "AAPL",
        "MSFT",
        "GOOGL",
        "AMZN"
    ]
}